Last reviewed · How we verify
Requip
At a glance
| Generic name | Requip |
|---|---|
| Sponsor | Boehringer Ingelheim |
| Target | D(1B) dopamine receptor, D(4) dopamine receptor, 5-hydroxytryptamine receptor 1A |
| Modality | Small molecule |
| Therapeutic area | Neuroscience |
| Phase | FDA-approved |
Approved indications
- Parkinson's disease
- Restless legs
Common side effects
- Dyskinesia
- Nausea
- Dizziness
- Hallucination
- Somnolence
- Abdominal pain/discomfort
- Orthostatic hypotension
- Vertigo
- Constipation
- Peripheral edema
- Back pain
- Diarrhea
Serious adverse events
- Hallucination
- Orthostatic hypotension
- Fall
Key clinical trials
- Infusion of Apomorphine: Long-term Safety Study (PHASE3)
- Gait Analysis in Neurological Disease
- Impact of Switching to Continuous Release Dopamine Agonists (PHASE3)
- Exercise Training Versus Ropinirole in Treating Restless Legs Syndrome Among Hemodialysis Patients (NA)
- Treatment of Hyperprolactinemia With the Non-ergoline Dopamine Agonist Ropinirole (PHASE1, PHASE2)
- Butrans for Treatment of Restless Legs Syndrome (PHASE4)
- Relative Bioavailability Study of Ropinirole Implants in Parkinson's Patients on L-Dopa Switched From Oral Ropinirole (PHASE1, PHASE2)
- Ropinirole for the Treatment of Muscle Cramps in Patients With Cirrhosis (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Requip CI brief — competitive landscape report
- Requip updates RSS · CI watch RSS
- Boehringer Ingelheim portfolio CI